Diabetes, GLP-1 Receptor Agonists, Glycemic Control, Extra Glicemic Effects, Weight Loss, Cardiovascular Risk. 1. Introduction. The glucagon-like peptide 1 (GLP-1) is an incretin hormone secreted mainly by the enteroendocrine cells of the intestine in response to glucose.
The combined therapy of GLP-1 receptor agonists (GLP-1RA) and basal insulin has emerged as an effective strategy for the management of type 2 diabetes mellitus (T2DM), offering benefits in glycated hemoglobin (HbA1c) reduction, weight control and a lower risk of hypoglycemia.
Common Side Effects of GLP-1 Agonists. GLP-1 receptor agonists, such as semaglutide and tirzepatide, are effective medications for managing obesity and type 2 diabetes.
Rates of type 2 diabetes are increasing rapidly worldwide. Treatment with GLP-1 agonists helps regulate blood glucose levels and decrease appetite to manage type 2 diabetes. However, the drugs break down rapidly in the body, so patients need regular oral tablets or injections.
Mounjaro (tirzepatide) is the first and only, once-weekly approved single-molecule GIP and GLP-1 receptor agonist that helps lower A1C for adults with type 2 diabetes.
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Receptor Agonists Benefits For Type 2 Diabetes.
Type 2 Diabetes.While GLP-1 receptor agonists are widely studied for their effectiveness in promoting weight loss, less is known about long-term weight maintenance after discontinuing the medication.
Because the improvements were observed among patients with type 2 diabetes as well, the authors believe GLP-1 receptor agonists benefits extend beyond glycemic control.
